Get the Stockscreener App
13.68
3.05%
-0.43
After Hours:
13.68
Amneal Pharmaceuticals Inc stock is traded at $13.68, with a volume of 4.46M.
It is down -3.05% in the last 24 hours and up +6.21% over the past month.
Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
See More
Previous Close:
$14.11
Open:
$14.03
24h Volume:
4.46M
Relative Volume:
1.90
Market Cap:
$4.30B
Revenue:
$2.68B
Net Income/Loss:
$-184.45M
P/E Ratio:
-20.10
EPS:
-0.6805
Net Cash Flow:
$229.23M
1W Performance:
+2.17%
1M Performance:
+6.21%
6M Performance:
+69.52%
1Y Performance:
+59.44%
1-Day Range:
$13.63
$14.03
1-Week Range:
$13.34
$15.00
52-Week Range:
$6.685
$15.00
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Name
Amneal Pharmaceuticals Inc
Sector
Phone
908-947-3120
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
13.68 | 4.44B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
124.82 | 53.64B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.23 | 54.24B | 29.62B | 260.04M | 5.51B | 0.0787 |
|
HLN
Haleon Plc Adr
|
10.47 | 45.87B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.08 | 37.94B | 17.39B | 1.43B | 774.28M | 1.219 |
|
UTHR
United Therapeutics Corp
|
469.49 | 20.14B | 3.13B | 1.27B | 1.12B | 26.39 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Overweight |
| Jun-06-25 | Initiated | Goldman | Buy |
| Feb-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Mar-08-21 | Upgrade | Goldman | Sell → Buy |
| Dec-14-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-27-20 | Initiated | Goldman | Sell |
| May-12-20 | Upgrade | Guggenheim | Sell → Neutral |
| Dec-12-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-12-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-08-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-21-19 | Upgrade | Raymond James | Mkt Perform → Strong Buy |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Mar-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Dec-14-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-16-18 | Downgrade | SunTrust | Buy → Hold |
| Aug-13-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-23-18 | Initiated | Morgan Stanley | Overweight |
| Jun-22-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Amneal Pharmaceuticals Inc Stock (AMRX) Latest News
Is It Too Late To Consider Amneal Pharmaceuticals (AMRX) After Its Strong Multi‑Year Share Price Run? - Yahoo Finance
Opioid Settlement And Index Inclusion Reframe Amneal Pharmaceuticals Risk And Reach - Yahoo Finance
Published on: 2026-01-30 06:37:48 - baoquankhu1.vn
Amneal initiates nationwide opioid settlement (AMRX:NASDAQ) - Seeking Alpha
Amneal Finalizes Nationwide Opioid Settlement Implementation Plan - TipRanks
Amneal Pharmaceuticals Added to S&P SmallCap 600® Index - The Manila Times
Amneal Pharma To Settle Majority Of Opioids-Related Claims - TradingView
Amneal Pharmaceuticals Finalizes Nationwide Opioids Settlement - TradingView
Amneal Pharmaceuticals, Inc. Added to S&P SmallCap 600® Index - Quiver Quantitative
Drugmaker Amneal joins S&P small-cap index investors track - Stock Titan
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report? - sharewise.com
TTM Technologies, Dutch Bros to join S&P 400 Index; Amneal, Apellis to be part of S&P SmallCap 600 (CIVI:NYSE) - Seeking Alpha
Amneal, LegalZoom, others rise as S&P Dow Jones Indices announces index changes - Investing.com Canada
TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600 - Benzinga
Amneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 1-Year HighStill a Buy? - MarketBeat
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026 - The Manila Times
Amneal Pharmaceuticals to detail 2025 results in Feb. 27 webcast - Stock Titan
Can Amneal Pharmaceuticals Inc. be the next market leaderWeekly Stock Report & Safe Entry Momentum Tips - mfd.ru
Risk Recap: Can Amneal Pharmaceuticals Inc. be the next market leaderNew Guidance & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Can Amneal Pharmaceuticals Inc. continue delivering strong returnsJuly 2025 Volume & AI Enhanced Trading Alerts - mfd.ru
Stock Recap: Is ACAD in a bullish channelJuly 2025 Short Interest & Smart Allocation Stock Reports - baoquankhu1.vn
Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Assessing Amneal Pharmaceuticals (AMRX) Valuation After Recent Share Price Momentum - Sahm
Truist raises PT on Amneal Pharmaceuticals (AMRX) to $15 from $14 - MSN
Profit Recap: Is Amneal Pharmaceuticals Inc in a long term uptrend2025 Geopolitical Influence & Advanced Technical Signal Analysis - baoquankhu1.vn
Amneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 12-Month HighHere's Why - MarketBeat
Amneal Pharmaceuticals stock hits 52-week high at $13.48 - Investing.com
Gains Recap: Is Amneal Pharmaceuticals Inc stock undervalued right nowCEO Change & Community Consensus Picks - baoquankhu1.vn
Geopolitics Watch: Should I buy KNTK stock nowWeekly Stock Analysis & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
3 Growth Companies With High Insider Ownership And Up To 79% Earnings Growth - simplywall.st
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Sees Large Increase in Short Interest - MarketBeat
Portfolio Recap: Can Amneal Pharmaceuticals Inc be the next market leader2025 Analyst Calls & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Amneal unveils new brand identity to reimagine access to medicine - MediaNews4U
Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock? - sharewise.com
Trade Recap: Is Amneal Pharmaceuticals Inc a potential multi baggerPortfolio Value Report & Real-Time Buy Signal Alerts - baoquankhu1.vn
Aug PostEarnings: Will Fastenal Company benefit from rate cutsRecession Risk & Trade Opportunity Analysis Reports - baoquankhu1.vn
Mycophenolate Pregnancy Registry: Key Insights for Investors - MSN
Is It Too Late To Consider Amneal Pharmaceuticals (AMRX) After Its Strong Multi‑Year Share Price Run - Yahoo Finance
Amneal unveils bold new brand to reimagine what’s possible in making medicine accessible for all - Pharmabiz.com
Amneal Pharmaceuticals Eyes 2026 Growth at JPMorgan, Crexont Sales Seen Doubling in 2025 - Yahoo Finance
Amneal Pharmaceuticals (NASDAQ:AMRX) Issues FY 2025 Earnings Guidance - MarketBeat
Amneal Pharmaceuticals Files Routine Regulation FD Disclosure Report - TipRanks
Amneal Pharma Expects To Meet Or Exceed Its 2025 Full-Year Financial Guidance - TradingView — Track All Markets
Is Amneal Pharmaceuticals Inc a strong candidate for buy and holdOil Prices & Safe Entry Zone Identification - baoquankhu1.vn
Keiferx collaborates with Amneal on KFRX-06 for Parkinson’s - BioWorld MedTech
Truist Raises PT on Amneal Pharmaceuticals (AMRX) to $15 From $14 - Insider Monkey
How interest rate cuts could boost Amneal Pharmaceuticals Inc. stockJuly 2025 Rallies & Free Fast Entry Momentum Trade Alerts - Улправда
Nasdaq Moves: Why Amneal Pharmaceuticals Inc. stock attracts global investorsJuly 2025 Levels & Weekly Stock Breakout Alerts - Улправда
Is Amneal Pharmaceuticals Inc. stock overvalued by current metricsWeekly Investment Recap & Precise Swing Trade Entry Alerts - ulpravda.ru
Will Amneal Pharmaceuticals Inc. stock recover faster than peersStability vs Neutral Overview & HOKA model picks for your routine - ulpravda.ru
Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.13%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):